Preview Mode

Home
> Stocks
> AMGN stock

Stay informed on AMGN stock with the most important news summaries, insider trading, valuation highlights and analyst recommendations

AMGN stock news: A summarized overview for you, just the bottom line of the most recent news items!

Last Updated: December 20, 2024
  • Why Amgen Inc. (AMGN) Stands Out as a Top Dividend Stock for Investors
    • Amgen Inc. (AMGN) is spotlighted as a top choice for dividend-focused investors due to its consistent performance and strong dividend track record, indicating financial stability and resourceful management committed to shareholder returns. 💰
    • The company's robust earnings and its potential for continued growth in the biotechnology sector offer promising signals for long-term investors, enhancing its appeal amidst economic uncertainties, thus making it a preferred option for those seeking reliable income streams.
    • With its strategic investments and innovative drug pipeline, Amgen exhibits significant future growth potential, which could bolster its dividend payouts, making it a compelling candidate for investors looking for a balance of security and growth in their investment portfolios.
  • In-Depth Analyst Report on Amgen Inc.: Key Insights for AMGN Investors
    • Amgen Inc. has reported robust financial performance driven by strong sales in its innovative biosimilar portfolio, highlighting a positive growth trajectory that could boost investor confidence in AMGN's future profitability.
    • Strategic acquisitions and expansion efforts are expected to enhance Amgen's pipeline and broaden its market presence, signaling potentially lucrative long-term gains for stakeholders as the company positions itself strategically within the pharmaceutical sector.
    • Despite some regulatory hurdles, ongoing research and development investments underline Amgen's commitment to innovation, suggesting that sustained focus on pioneering solutions could provide competitive advantages and drive shareholder value.

Real-time price chart of AMGN stock

Stay up-to-date with the latest performance of Amgen, (AMGN) through our real-time stock chart, providing live insights into its market movements

AMGN stock valuation - less noise, just the highlights

  • The price-to-sales (P/S) ratio of 4.34 is relatively low when you consider the biotechnology industry's norms, indicating that AMGN is undervalued relative to its sales revenue. Investors looking for a stock with high revenue generation efficiency will find this aspect of Amgen valuation appealing.
  • AMGN's forward P/E ratio of 12.59 is a strong indicator of its favorable valuation compared to its current P/E of 33.44, suggesting that future earnings are expected to significantly increase, making it an attractive option for investors focused on growth potential and improving profitability. This points to a positive outlook for Amgen valuation.
  • Despite the company having a higher PEG ratio of 6.69, AMGN's EPS growth estimate for the next year at 5.99% and for the next 5 years at 5.00% presents a balanced growth scenario. This aspect highlights a steady growth trajectory in earnings, making it a considerable choice for those evaluating AMGN valuation with a long-term strategy in mind.

Stay informed with the latest AMGN stock analyst recommendations:

  • Several analysts, like Barclays and William Blair, have upgraded their Amgen recommendations since mid-2023, moving from Underweight and Market Perform respectively to more positive outlooks, such as Equal Weight and Outperform. These upgrades, paired with increased price targets, indicate a growing confidence among some analysts in Amgen's market positioning.
  • The Amgen analyst recommendation from BofA Securities, which resumed its rating at Underperform with a price target of $256, contrasts sharply with Cantor Fitzgerald's earlier initiation at Overweight with a $405 target. This disparity underscores the varied perspectives analysts hold on AMGN's valuation and potential.
  • Amgen (AMGN) analyst recommendations have shown notable volatility over the past year, highlighting differing views on its potential growth. Recent changes include BMO Capital Markets upgrading from Market Perform to Outperform, accompanied by a price target increase to $326, suggesting optimism about Amgen's future performance.

Stay updated on AMGN stock insider trading with these key points:

  • 1. Monitoring insider trading activities, such as those by high-level executives like the Senior Vice President & Chief Compliance Officer Nancy Grygiel, can provide significant insights for investors. In this instance, the sale of 2,117 shares at a transaction cost of $313.09 per share might signal a potential concern about AMGN’s short-term stock price from someone with key inside information. Keep an eye on further insider activity to confirm trends.
  • 2. The sale of shares constituting a substantial portion of their holdings can be a strong indicator for investors to re-evaluate their positions. In this case, the insider sale represents over 20% of Grygiel's total shares (with 9,883 remaining shares), which is significant. Traders using 'AMGN insider trading' trends could interpret these large sales as a possible sell signal, suggesting a reevaluation of AMGN stock in their portfolios.
  • 3. High-ranking roles in finance or legal positions, such as the SVP & CCO for Amgen, are critical to observe in insider trades because they can reflect strategic company perspectives. Nancy Grygiel's recent trade might have been prompted by potential upcoming challenges or other strategic shifts within Amgen. Investors should consider further analysis of Amgen insider trades to predict broader market behaviors and make informed decisions.

AMGN technical analysis

Unlock insights to make smarter investment decisions with this real-time technical analysis tool. Dive in to see the latest buy and sell signals tailored for today's dynamic market. Get the market's inside scoop in a flash! Peek at our fun and user-friendly ratings to see what it is whispering about your AMGN stock, within various timeframes.

Join the Discussion: What's your outlook on AMGN stock's performance?

Are you considering investing in AMGN or have you already done so? Share your thoughts below with the investor and trader community at ForexLive.com, share your angles, analysis, predictions, or questions about AMGN in the comments below! Your input matters to us.

Please note that this content regarding AMGN stock is for informational purposes only, includes opinions and not recommendations, and is not intended as investment or trading advice; invest in and/or trade AMGN at your own risk only.

Explore additional stocks:

Discover Ameriprise Financial stock with its new summaries, insider trading, valuation highlights and analyst recommendations

GMT 00:00:00
LON 00:00:00
NY 00:00:00
TKYO 00:00:00
SYD 00:00:00

Stock Daily Updates

Must Read

Follow Us

Read our Terms, Cookies and Privacy Notice

Manage cookies

High risk warning: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all your initial investment; do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading and seek advice from an independent financial or tax advisor if you have any questions.

Advisory warning: FOREXLIVE™ is not an investment advisor, FOREXLIVE™ provides references and links to selected news, blogs and other sources of economic and market information for informational purposes and as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and FOREXLIVE™ specifically hereby acknowledges clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Forex dealer. Any news, opinions, research, data, or other information contained within this website is provided on an "as-is" basis as a general market commentary and does not constitute investment or trading advice, and we do not purport to present the entire relevant or available public information with respect to a specific market or security. FOREXLIVE™ expressly disclaims any liability for any lost principal or profits which may arise directly or indirectly from the use of or reliance on such information, or with respect to any of the content presented within its website, nor its editorial choices.

Disclaimer: FOREXLIVE™ may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Finance Magnates CY Limited

!"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}